Evidence and safety
7-OH: Concentrated Products & Regulatory Questions
7-OH is shorthand for 7-hydroxymitragynine. Concentrated products marketed for 7-OH should not be treated as interchangeable with ordinary kratom leaf.
By Kratom Finder Editorial · Updated . Source-based editorial update; no new clinician review is claimed.
Identify the actual product
Check the ingredient list and measured alkaloid amounts, not just the word “kratom.” A tablet, shot, powder, or capsule may contain a very different composition from another product using the same brand name.
Do not convert potency slogans into doses
Comparisons with morphine or claims such as “extra strength” may mix laboratory results with marketing. They do not provide a safe human dose conversion or prove a retail product’s effects.
What the FDA announced
The FDA recommended federal scheduling action for certain 7-OH products in July 2025 and has taken enforcement actions. DEA subsequently announced threshold proceedings in July 2026 and scheduled three related compounds in August. These are separate actions; read the linked timeline and official documents for the substance, scope, and effective date.
Care and product information
Seek clinical advice about use, interactions, dependence, or withdrawal. Bring the packaging and batch information. For a seizure, collapse, or breathing problems, seek emergency help.
Sources
- FDA: FDA and Kratom
- NIH NCCIH: Kratom
- NIDA: Kratom research and health effects
- FDA and DEA timeline: dated source documents through August 2026
- FDA: December 2025 enforcement and July recommendation
Sources support the stated facts; they do not validate an individual product or replace personal medical care. Report a correction.
Related information
Safety overview · All articles · State rules · Store directory